• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氨氯地平/缬沙坦混悬液的临时调配与生理模型构建

Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension.

作者信息

Aabed Wafa' J, Radwan Asma H, Zaid Abdel Naser, Shraim Naser Y

机构信息

Department of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, State of Palestine.

出版信息

Int J Hypertens. 2021 Mar 12;2021:6695744. doi: 10.1155/2021/6695744. eCollection 2021.

DOI:10.1155/2021/6695744
PMID:33824764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8007339/
Abstract

METHOD

Amlodipine/valsartan extemporaneous suspension was prepared from available commercial tablets such as Valzadepine. The dissolution profiles for the extemporaneous preparation and the commercial tablet were determined in different pH media. The physical, chemical, and microbial stability of the compounded formulation was evaluated over one-month period at room temperature. Moreover, modeling using GastroPlus™ software was used to build absorption models for both drugs based on the dissolution data. The simulated plasma profiles for both active ingredients were compared with the plasma profiles to examine the similarity of the extemporaneous suspension and the commercial tablets.

RESULTS

The amlodipine/valsartan extemporaneous suspension was successfully prepared with acceptable organoleptic properties. The suspension was stable for four-week period preserving its physical and chemical features. The release profiles of valsartan and amlodipine from the suspension were similar to those from source tablet Valzadepine. modeling predicted the similarity of the extemporaneous suspension and the commercial tablets.

CONCLUSION

Amlodipine/valsartan extemporaneous suspension could be prepared from available commercial tablets. Moreover, GastroPlus™ can be applied along with the dissolution in order to affirm similarity in extemporaneous compounding situations.

摘要

方法

氨氯地平/缬沙坦临时混悬剂由市售片剂(如Valzadepine)制备而成。测定了临时制剂和市售片剂在不同pH介质中的溶出曲线。在室温下对复方制剂的物理、化学和微生物稳定性进行了为期一个月的评估。此外,使用GastroPlus™软件进行建模,根据溶出数据建立两种药物的吸收模型。将两种活性成分的模拟血浆曲线与血浆曲线进行比较,以检验临时混悬剂与市售片剂的相似性。

结果

成功制备了具有可接受感官特性的氨氯地平/缬沙坦临时混悬剂。该混悬剂在四周内保持稳定,其物理和化学特性未发生改变。缬沙坦和氨氯地平从混悬剂中的释放曲线与源片剂Valzadepine相似。建模预测了临时混悬剂与市售片剂的相似性。

结论

氨氯地平/缬沙坦临时混悬剂可由市售片剂制备而成。此外,GastroPlus™可与溶出度测定一起应用,以确认临时复方制剂的相似性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/47b1dd97a8f2/ijhy2021-6695744.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/c55a7a758549/ijhy2021-6695744.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/232283bbe4a2/ijhy2021-6695744.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/47b1dd97a8f2/ijhy2021-6695744.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/c55a7a758549/ijhy2021-6695744.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/232283bbe4a2/ijhy2021-6695744.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62f/8007339/47b1dd97a8f2/ijhy2021-6695744.003.jpg

相似文献

1
Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension.氨氯地平/缬沙坦混悬液的临时调配与生理模型构建
Int J Hypertens. 2021 Mar 12;2021:6695744. doi: 10.1155/2021/6695744. eCollection 2021.
2
Preparation and stability evaluation of extemporaneous oral suspension of valsartan using commercially available tablets.使用市售片剂制备缬沙坦临时口服混悬液并进行稳定性评估。
Int J Pharm Compd. 2014 Mar-Apr;18(2):169-74.
3
Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder.使用片剂或纯粉末对阿托伐他汀临时口服混悬液进行配制及稳定性评估。
Eur J Hosp Pharm. 2017 May;24(3):157-161. doi: 10.1136/ejhpharm-2016-000913. Epub 2016 Jun 15.
4
Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.比索洛尔的患者友好型临时制剂:在稳定性和生物利用度研究中的应用
Drug Deliv Transl Res. 2023 Mar;13(3):795-810. doi: 10.1007/s13346-022-01239-x. Epub 2022 Oct 3.
5
Stability of extemporaneously prepared rosuvastatin oral suspension.瑞舒伐他汀临时配制口服混悬液的稳定性。
Am J Health Syst Pharm. 2017 Oct 1;74(19):1579-1583. doi: 10.2146/ajhp160235.
6
Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.卡托普利速释口崩片替代制剂与口服液体制剂的稳定性比较。
Clin Ther. 2012 Nov;34(11):2221-9. doi: 10.1016/j.clinthera.2012.10.005.
7
Investigation of the Physical, Chemical and Microbiological Stability of Losartan Potassium 5 mg/mL Extemporaneous Oral Liquid Suspension.氯沙坦钾 5mg/mL 口服混悬液的物理、化学和微生物稳定性研究。
Molecules. 2021 Jan 8;26(2):301. doi: 10.3390/molecules26020301.
8
Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.由市售片剂制备的即配苯硝唑口服混悬液用于治疗小儿恰加斯病。
Trop Med Int Health. 2015 Jul;20(7):864-70. doi: 10.1111/tmi.12508. Epub 2015 Apr 6.
9
Formulation and stability of diazepam suspension compounded from tablets.由片剂配制的地西泮混悬液的处方及稳定性
Am J Hosp Pharm. 1986 Jun;43(6):1489-91.
10
The stability of quetiapine oral suspension compounded from commercially available tablets.市售片剂制备的喹硫平口服混悬液的稳定性。
PLoS One. 2021 Aug 10;16(8):e0255963. doi: 10.1371/journal.pone.0255963. eCollection 2021.

引用本文的文献

1
Engineering stable Amlodipine suspensions for flexible compounding at King Khaled University Hospital.在沙特国王哈立德大学医院制备用于灵活配药的稳定氨氯地平混悬剂。
Saudi Pharm J. 2025 Jul 8;33(4):23. doi: 10.1007/s44446-025-00028-0.
2
Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient's Safety-A Narrative Review.儿科心脏病学中口服液体制剂的稳定性:患者安全的先决条件——一篇叙述性综述。
Pharmaceutics. 2023 Apr 21;15(4):1306. doi: 10.3390/pharmaceutics15041306.

本文引用的文献

1
Quantitative model for the blood pressure-lowering interaction of valsartan and amlodipine.缬沙坦与氨氯地平降压相互作用的定量模型
Br J Clin Pharmacol. 2016 Dec;82(6):1557-1567. doi: 10.1111/bcp.13082. Epub 2016 Oct 3.
2
Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation.缬沙坦纳米晶体的时间治疗学调制脉冲系统——体外和体内评价
AAPS PharmSciTech. 2017 Feb;18(2):349-357. doi: 10.1208/s12249-016-0511-5. Epub 2016 Mar 9.
3
In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model.
用于药物吸收研究的大鼠结肠原位灌注模型:与小肠和Caco-2细胞模型的比较
J Pharm Sci. 2015 Sep;104(9):3136-45. doi: 10.1002/jps.24447. Epub 2015 Apr 17.
4
Preparation and stability evaluation of extemporaneous oral suspension of valsartan using commercially available tablets.使用市售片剂制备缬沙坦临时口服混悬液并进行稳定性评估。
Int J Pharm Compd. 2014 Mar-Apr;18(2):169-74.
5
Pediatric drug development: formulation considerations.儿科药物研发:剂型考量
Drug Dev Ind Pharm. 2014 Oct;40(10):1283-99. doi: 10.3109/03639045.2013.850713. Epub 2014 Jan 31.
6
In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.采用 GastroPlus®建立依非韦伦片的体外-体内相关性。
AAPS PharmSciTech. 2013 Sep;14(3):1244-54. doi: 10.1208/s12249-013-0016-4. Epub 2013 Aug 14.
7
Tablet splitting and weight uniformity of half-tablets of 4 medications in pharmacy practice.药房实践中4种药物片剂分割及半片重量均匀性
J Pharm Pract. 2012 Aug;25(4):471-6. doi: 10.1177/0897190012442716. Epub 2012 Apr 27.
8
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension.缬沙坦治疗 6 至 16 岁儿童高血压的有效性和安全性。
J Clin Hypertens (Greenwich). 2011 May;13(5):357-65. doi: 10.1111/j.1751-7176.2011.00432.x. Epub 2011 Mar 18.
9
Preparation and bioavailability assessment of SMEDDS containing valsartan.含缬沙坦的 SMEDDS 的制备及生物利用度评价。
AAPS PharmSciTech. 2010 Mar;11(1):314-21. doi: 10.1208/s12249-010-9385-0. Epub 2010 Feb 25.
10
Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.氨氯地平/缬沙坦初始联合治疗与氨氯地平单药治疗相比在2期高血压黑人患者中的疗效和安全性:EX-STAND研究
J Hum Hypertens. 2009 Jul;23(7):479-89. doi: 10.1038/jhh.2008.153. Epub 2009 Jan 29.